The loss of the state’s EDGE Fund has meant less funding opportunities for the state’s bioscience companies such as Caisson Biotech and Selexys Pharmaceuticals.
News
The loss of the state’s EDGE Fund has meant less funding opportunities for the state’s bioscience companies such as Caisson Biotech and Selexys Pharmaceuticals.
